The recognition and diagnosis and management of anemia & hyperphosphatemia in CKD: Filtering it down to what the clinician needs to know

Cost: Free

View Offer chevron_right

Details

Activity Description / Statement of Need:

In this online, self-learning activity:

 Chronic kidney disease (CKD) affects about 15% of the general population in the United States and is the tenth-leading cause of death, accounting for 52,260 deaths in 2020. Along with the risk for end-stage kidney disease (ESKD) and cardiovascular disease (CVD), CKD has also been associated with a number of complications, including anemia and hyperphosphatemia. Anemia occurs in about 15% of patients with CKD and arises from decreased erythropoiesis and abnormal iron metabolism. Hyperphosphatemia occurs in the later stages of CKD because the kidney is the primary method by which the body maintains phosphate. This retention of phosphate leads to the development of CKD-mineral bone disorder (CKD-MBD), with the literature suggesting that hyperphosphatemia occurs in a large portion of patients on dialysis based on phosphate binder (PB) usage.

This learning activity has been designed to bring HCPs’ knowledge of the treatment and screening of anemia and hyperphosphatemia in patients with CKD up to date and to improve their competence and performance in treating it. It will walk participants through treatment pathways and review of the evidence behind therapies to treat CKD’s complications.

Target Audience:

The following HCPs: nephrologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in nephrology; and any other HCPs with an interest in or who clinically encounter patients with CKD.

Stay up-to-date

Receive special offers, keep up with MOC requirements and stay informed of the latest offerings in free online CME in your specialty.